Supplements for MCAS and Histamine Intolerance | The EDS Clinic

Scientists Like Me Knew There Was Something Amiss With Andrew Huberman’s Wildly Popular Podcast

He recommends supplements. He’s iffy on the flu shot. And more.

Research update: The relation between ME/CFS disease burden and research funding in the USA

BACKGROUND: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating, chronic, multisystem disease that affects an estimated 1 to 2.5 milli...

Microbiome transplants may curb food allergies

Gut microbe transplants treated some peanut allergies in an early-stage clinical trial.

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Essentials of Diagnosis and Management

Despite myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) affecting millions of people worldwide, many clinicians lack the knowledge to appropriately diagnose or manage ME/CFS. Unfortunately, clinical guidance has been scarce, obsolete, or potentially harmful. Consequently, up to 91% of patients in the United States remain undiagnosed, and those diagnosed often receive inappropriate treatment. These problems are of increasing importance because after acute COVID-19, a significant percentage of people remain ill for many months with an illness similar to ME/CFS.

People Say These Peptides Hurt Them. Their Stories Are Muffled in MAHA’s Push for Medical Freedom. - KFF Health News

People who have taken experimental peptides, such as BPC-157, complain of migraines, eye pain, fatigue, and more. Learning whether these popular but unproven drugs are to blame may become harder if Robert F. Kennedy Jr. fulfills a promise to make them more accessible.

COVID antihistamine protocol

This current wave of COVID is bad, and I'm seeing a lot of people who were previously NOVID posting photos of their positive tests. I've been trying fairly diligently to get this information out on social media, because I know I follow the literature a lot more closely than a lot of people, so here

Patient-reported treatment outcomes in ME/CFS and long COVID

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and long COVID are persistent multisystem illnesses affecting many patients. With no known effective FDA-approved treatments for either condition, patient-reported outcomes of treatments may prove helpful in identifying management strategies that can improve patient care and generate new avenues for research. Here, we present the results of an ME/CFS and long COVID treatment survey with responses from 3,925 patients. We assess the experiences of these patients with more than 150 treatments in conjunction with their demographics, symptoms, and comorbidities. Treatments with the greatest perceived benefits are identified. Patients with each condition who participated in the study shared similar symptom profiles, including all the core symptoms of ME/CFS, e.g., 89.7% of ME/CFS and 79.4% of long COVID reported postexertional malaise (PEM). Furthermore, treatment responses between these two patient groups were significantly correlated (R 2 = 0.68). Patient subgroups, characterized by distinct symptom profiles and comorbidities, exhibited increased responses to specific treatments, e.g., a POTS-dominant cluster benefiting from autonomic modulators and a cognitive-dysfunction cluster from CNS stimulants. This study underscores the symptomatic and therapeutic similarities between ME/CFS and long COVID and highlights the commonalities and nuanced complexities of infection-associated chronic diseases and related conditions. While this study does not provide recommendations for specific therapies, in the absence of approved treatments, insights from patient-reported experiences provide urgently needed real-world evidence for developing targeted patient care therapies and future clinical trials.

Ayurveda Doctor Surrey BC | Jaisri M. Lambert, NAMA Certified | Ayurveda‑Seminars.com

Book an Ayurveda consultation in Surrey, BC with Dr. Jaisri M. Lambert NAMA certified, 35+ years experience in pulse assessment, Panchakarma & Turiya Therapy. Online & in‑person mentorship available.

OTC nasal spray reduces the risk of COVID-19 infection by 70%

The active ingredient in a common over-the-counter allergy spray may do more than ease hay fever symptoms. A new clinical trial found azelastine cut COVID-19 infections by 70%, hinting at a cheap, accessible way to add protection alongside vaccines.

Treating Allergic Rhinitis Improves Symptoms of ADHD - ENTtoday

Children with allergic rhinitis and attention-deficit/hyperactivity disorder (ADHD) should initially be treated for their allergic rhinitis and then monitored for improvement in ADHD symptoms

Long-term maintenance treatment with 300 mg thiamine for fatigue in patients with inflammatory bowel disease: results from an open-label extension of the TARIF study

OBJECTIVE AND AIMS: Fatigue is common in inflammatory bowel disease (IBD). In a RCT we demonstrated reductions in fatigue after 4 weeks' treatment with high-dose oral thiamine. We aimed to investigate whether 300 mg thiamine daily for 12 weeks could maintain the achieved levels of fatigue in patients with IBD after a 4-week intervention with high-dose thiamine; and evaluate the effect of a 6-month period where patients were free to take oral thiamine. METHODS: A randomised, open-label, controlled trial, performed as a long-term extension (LTE) study of an initial randomised, high-dose thiamine trial. Patients were allocated 1:1 to 300 mg oral thiamine or no thiamine for 12 weeks. Subsequently, the patients were allowed to self-treat with over-the-counter (OTC) oral thiamine 6-month. RESULTS: Regardless of allocation in the LTE study fatigue severity increased in the study period. No significant effect of 300 mg oral thiamine were found, when stratifying for initial allocation in the high-dose study or fatigue level at entry in the LTE study. Patients who took OTC thiamine had lower level of fatigue 6 month later (7.8; 95% CI: 5.5-10.1) when compared to the remains (11.0; 95% CI: 9.2-12.8) (p = .02). After the 6-months follow-up without restrictions, 66% of patients had reached normal fatigue levels. CONCLUSIONS: We found no beneficial effect on fatigue from thiamine taken in doses of 300 mg per day for 12 weeks following high-dose treatment. After a 6-months follow-up without restrictions 66% had reached a normal level of fatigue. CLINICAL TRIAL REGISTRATION: The trial was registered at ClinicalTrials.gov under study identifier NCT03634735.

‘You don’t want to get better’: the outdated treatment of ME/CFS patients is a national scandal | George Monbiot

The notion that this illness is psychosomatic is having devastating effects, says Guardian columnist George Monbiot

The negative impact of the psychiatric model of chronic fatigue syndrome on doctors’ understanding and management of the illness

Background: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a disabling condition that greatly impacts the lives of sufferers. Many sufferers report problems getting a confirmatory d...

RFK Jr. to Allow Broad Use of Unapproved Peptide Injections

In a unilateral declaration by the health secretary, several injections promoted by online influencers will become widely available. The F.D.A. had advised against the move.

Matthew Schrag, MD, PhD | Department of Neurology

Vanderbilt University Medical Center 1211 Medical Center Drive, Nashville, TN 37232 (615) 322-5000